「小普日报」2023年11月09日热点速递
关键词 帕博利珠单抗 司帕生坦 厄贝沙坦 齐泊腾坦 达格列净 阿替利珠单抗 贝伐珠单抗 奥妥珠单抗 基因检测 格菲妥单抗 赛帕利单抗
#今日行业热点#
①The Lancet：Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial 临床试验：帕博利珠单抗（Pembrolizumab）联合化疗对比与化疗用于晚期胸膜间皮瘤的比较:一项Ⅲ期、开放标签、随机对照试验 DOI: 10.1016/S0140-6736(23)01613-6
Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial - The Lancet
②The Lancet：Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial 临床试验：司帕生坦（Sparsentan）与厄贝沙坦（Irbesartan）用于IgA肾病的疗效和安全性比较(PROTECT):一项随机、活性药对照、Ⅲ期试验的2年结果 DOI: 10.1016/S0140-6736(23)02302-4
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial - The Lancet
③The Lancet：Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial 临床试验：齐泊腾坦(Zibotentan)联合达格列净对比达格列净单药用于慢性肾脏病(ZENITH-CKD)的比较:一项多中心、随机、活性药对照、Ⅱb期临床试验 DOI: 10.1016/S0140-6736(23)02230-4
Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial - The Lancet
④The Lancet Oncology：Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study 研究：基于人工智能的病理学作为肝细胞癌患者对阿替利珠单抗-贝伐珠单抗敏感性的生物标志物:一项多中心回顾性研究 DOI: 10.1016/S1470-2045(23)00468-0
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study - The Lancet Oncology
⑤The Lancet Oncology：Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial 临床数据：BTK抑制剂伊布替尼联合维奈托克(venetoclax)对比苯丁酸氮芥联合奥妥珠单抗（Obinutuzumab）用于慢性淋巴细胞白血病(GLOW)的一项多中心、开放标签、随机、Ⅲ期试验的4年随访 DOI: 10.1016/S1470-2045(23)00452-7
Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
⑥The Lancet Gastroenterology and Hepatology：Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management 综述：从息肉病综合征和基因、基因检测和临床管理看胃肠道息肉病领域的最新进展和挑战 DOI: 10.1016/S2468-1253(23)00240-6
Genetic predisposition to gastrointestinal polyposis: syndromes, tumour features, genetic testing, and clinical management - The Lancet Gastroenterology & Hepatology
⑦CD20/CD3靶向的T细胞双特异性抗体格菲妥单抗（Glofitamab ）获国家药监局附条件批准上市，用于复发或难治性弥漫大B细胞淋巴瘤（DLBCL） ⑧JAK1抑制剂乌帕替尼注册III期试验，拟评估用于非节段性白癜风（NSV）的有效性与安全性 ⑨TIGIT抗体Domvanalimab与PD-1抗体赛帕利单抗（Zimberelimab）联合铂类药物用于转移性胃、胃食管连接部或食管腺癌患者的Ⅱ期EDGE-Gastric临床结果积极 ⑩TYK2抑制剂VTX958用于中重度斑块型银屑病的Ⅱ期临床达到主要终点和所有次要终点，但由于效果未达到研究内部目标，此项Ⅱ期试验已被终止 科学探索的世界充满挑战，AtaGenix致敬每一位拓荒者，更致力于成为您信赖的合作伙伴！
